Skip to content

Observation of the effectiveness of 0.05% cyclosporine eye drops (II) in the treatment of dry eye patients after refractive surgery

Observation of the effectiveness of 0.05% cyclosporine eye drops (II) in the treatment of dry eye patients after refractive surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084341
Enrollment
Unknown
Registered
2024-05-14
Start date
2024-05-21
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DRY EYE

Interventions

Experimental group:Drug intervention was used in this study. Specific intervention measures: 80 patients with ametropia who intended to undergo Smile full femtosecond surgery without obvious dry eyes
Control group: Only 0.1% sodium hyaluronate was treated 4 times a day.
Control group:Control group, 40 cases, were included in the right eye observation. All patients were treated with levofloxacin combined with loteprednol eye drops four times a day within one week afte

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Eighty patients with Smile total femtoseconds were included, and 40 patients in the test group and 40 patients in the control group were included in the right eye for observation. Inclusion criteria: (1) Age 18-60 years old; (2) Preoperative diopter, myopia = -12.00D, astigmatism = 6.00D; (3) On the basis of full understanding, the patient voluntarily participates in the research observation and signs the informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) entropebral, ectropion, trichiasis, corneal ulcer, trachoma, keratitis, blepharitis/meibomian adenitis, blepharitis/meibomian gland cyst, ocular trauma, lesions caused by corneal foreign bodies, burns, dacryocystitis and other infections, etc. (2) Patients with glaucoma; (3) Allergic to this product; (4) Patients with serious primary diseases and mental disorders such as liver, kidney and hematopoietic system; (5) Pregnant and lactating women; (6) The researcher considers it inappropriate to participate in the researcher; (7) Those who do not sign the informed consent.

Design outcomes

Primary

MeasureTime frame
OSDI;

Secondary

MeasureTime frame
FS;BUT;Schirmer ;VA;IOP;SRI;SAI;

Countries

CHINA

Contacts

Public ContactLI YING

Peking Union Medical College Hospital

liyingpumch@126.com+86 138 0130 9545

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026